2015-005450-36
Pilot to Evaluate the Safety and Efficacy of Abatacept in Adults and Children Over the Age of 6 With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Bristol-Myers Squibb Company·EU Clinical Trials Register
Study focus
- Disease/Condition
- Rheumatoid Arthritis
Sponsor & location
- Primary sponsor
- Bristol-Myers Squibb Company
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
• Kidney diseases other than FSGS or MCD
ICD-10 classifications
Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2015-005450-36
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2015-005450-36 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb Company and is currently status unknown. The study focuses on Rheumatoid Arthritis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.